摘要
背景:多发性骨髓瘤患者患有免疫系统失调,针对免疫系统(例如单克隆抗体或特异性细胞治疗如CAR-T细胞)的新治疗方案进入临床实践,但是耗尽的免疫系统阻碍了更有效的免疫治疗。针对微环境中的免疫功能障碍可能是免疫介导治疗的潜在靶标。 方法:在这里,我们回顾当前关于在耗尽的T和B细胞表面表达的程序性死亡1(PD-1)受体的文献和知识,其配体PD-L1在骨髓瘤细胞上表达并抑制T细胞介导细胞凋亡。 结果:程序性死亡1(PD-1)受体在耗尽的T和B细胞表面表达,其配体PD-L1在骨髓瘤细胞上表达并抑制T细胞介导的细胞凋亡。近来,通过单克隆抗体抑制这种“检查点”已经显示在实体瘤和恶性淋巴瘤中的高活性。在多发性骨髓瘤患者中,PD-L1在骨髓瘤细胞上过表达,PD1在T细胞上表达,表明PD-1 / PD-L1在免疫抑制微环境中起主要作用。 结论:使用抗PD-1 / PD-L1策略的免疫治疗是多发性骨髓瘤患者的有希望的治疗方案。
关键词: Coinhibitory分子PD-1,微环境,多发性骨髓瘤,T细胞介导的凋亡,PD-L1,免疫抑制。
Current Cancer Drug Targets
Title:Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Volume: 17 Issue: 9
关键词: Coinhibitory分子PD-1,微环境,多发性骨髓瘤,T细胞介导的凋亡,PD-L1,免疫抑制。
摘要: Background: Patients with Multiple Myeloma suffer from dysregulation of the immune system and new therapeutic options targeting the immune systems such as monoclonal antibodies or specific Cell therapy such as CAR-T cells have entered clinical practice, but the exhausted immune system hampered a more effective immunotherapy. Targeting the immunological dysfunction in the microenviroment might be a potential target for immune-mediated therapies.
Method: Here we review the current literature and knowledge about the programmed death 1 (PD-1) receptor which is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on myeloma cells and inhibits T cell-mediated apoptosis.
Results: The programmed death 1 (PD-1) receptor is expressed on the surface of exhausted T and B cells and its ligand PD-L1 is expressed on myeloma cells and inhibits Tcell-mediated apoptosis. Inhibiting such “checkpoint” by monoclonal antibodies recently has been shown high activity in solid tumors and malignant lymphomas. In patients with multiple myelomaPD-L1 is overexpressed on myeloma cells and PD1 on T-cells suggesting an active role of PD-1/PD-L1 in the immunosuppressive microenvironment.
Conclusion: Immunotherapies using anti-PD-1/PD-L1 strategies are a promising treatment options for patients with multiple myeloma.
Export Options
About this article
Cite this article as:
Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma, Current Cancer Drug Targets 2017; 17 (9) . https://dx.doi.org/10.2174/1568009617666170906170348
DOI https://dx.doi.org/10.2174/1568009617666170906170348 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews The Role of Flavonoids in Inhibiting IL-6 and Inflammatory Arthritis
Current Topics in Medicinal Chemistry Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cardiology Reviews NEAT1: A Novel Long Non-coding RNA Involved in Mediating Type 2 Diabetes and its Various Complications
Current Pharmaceutical Design Cardiovascular Proteomics
Current Proteomics Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Promising Protective Effects of Chrysin in Cardiometabolic Diseases
Current Drug Targets Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management
Current Genomics Protective Effects of Curcumin against Iron-induced Toxicity
Current Pharmaceutical Biotechnology Epidermolysis Bullosa: Pediatric Perspectives
Current Pediatric Reviews Fragmented ECG as a Risk Marker in Cardiovascular Diseases
Current Cardiology Reviews Control of Copper Status for Cancer Therapy
Current Cancer Drug Targets Meet Our Editorial Board Member:
Current Drug Targets Regulatory Mechanisms of Vanillic Acid in Cardiovascular Diseases: A Review
Current Medicinal Chemistry Expression of microRNAs (133b and 138) and Correlation with Echocardiographic Parameters in Patients with Alcoholic Cardiomyopathy
MicroRNA p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Uric Acid and Oxidative Stress
Current Pharmaceutical Design